Search Results - "Patel, Dipak R."

Effect of Bamlanivimab as Monotherapy or in Combination with Etesevimab or Sotrovimab on Persistently High Viral Load in Patients with Mild-to-Moderate COVID-19: A Randomized, Phase 2 BLAZE-4 Trial by Nichols, Russell M., Macpherson, Lisa, Patel, Dipak R., Yeh, Wendy W., Peppercorn, Amanda

“…Introduction Treatment with monoclonal antibodies provides rapid, passive immunity and may stop COVID-19 disease progression. The study evaluated the effect of…”
Get full text

Endogenous Antibody Responses to SARS-CoV-2 in Patients With Mild or Moderate COVID-19 Who Received Bamlanivimab Alone or Bamlanivimab and Etesevimab Together by Zhang, Lin, Poorbaugh, Josh, Dougan, Michael, Chen, Peter, Gottlieb, Robert L, Huhn, Gregory, Beasley, Stephanie, Daniels, Montanea, Ngoc Vy Trinh, Thi, Crisp, Melissa, Freitas, Joshua Joaquin, Vaillancourt, Peter, Patel, Dipak R, Nirula, Ajay, Kallewaard, Nicole L, Higgs, Richard E, Benschop, Robert J

“…Neutralizing monoclonal antibodies (mAbs) to SARS-CoV-2 are clinically efficacious when administered early, decreasing hospitalization and mortality in…”
Get full text

Efficacy and Safety of Low-Dose, Rapidly Infused Bamlanivimab and Etesevimab: Phase 3 BLAZE-1 Trial for Mild-to-Moderate COVID-19 by Patel, Dipak R., Macpherson, Lisa, Bohm, Martin, Upadhyaya, Himanshu, Deveau, Carmen, Nirula, Ajay, Klekotka, Paul, Williams, Mark, Hufford, Matthew M.

“…Introduction The monoclonal antibody therapies bamlanivimab (BAM) + etesevimab (ETE) received emergency use authorization (EUA) from the US Food and Drug…”
Get full text

PK/PD modeling links accelerated resolution of COVID‐19‐related clinical symptoms to SARS‐CoV‐2 viral load reduction in patients following treatment with Bamlanivimab alone or Bamlanivimab and Etesevimab together by Ernest, C. Steven, Chien, Jenny Y., Patel, Dipak R., Chigutsa, Emmanuel

“…The relationship between severe acute respiratory syndrome‐coronavirus 2 (SARS‐CoV‐2) viral load reduction and disease symptom resolution remains largely…”
Get full text

Characterization of LY2775240, a selective phosphodiesterase‐4 inhibitor, in nonclinical models and in healthy subjects by Patel, Dipak R., Urva, Shweta, Ho, Stephen, Buckman, Cody J., Ma, Yanfei, Lim, Jean, Sissons, Sean E., Zuniga, Mary S., Philips, Diane, Cox, Karen, Dairaghi, Daniel J.

“…LY2775240 is a highly selective, potent and orally‐administered inhibitor of phosphodiesterase 4 (PDE4), and is being investigated as a treatment option for…”
Get full text

Pharmacokinetics, Efficacy, and Safety of a SARS-CoV-2 Antibody Treatment in Pediatric Participants: An Open-Label Addendum of a Placebo-Controlled, Randomized Phase 2/3 Trial by Upadhyaya, Himanshu P., Chien, Jenny Y., Long, Amanda J., Bohm, Martin S., Kallewaard, Nicole L., Macpherson, Lisa F., Patel, Dipak R., Hufford, Matthew M., Krull, Constance J., Ang, Jocelyn Y., Chen, Peter, Muller, William J., Potts, Jeffrey A., Quinn, Timothy, Williams, Mark

“…Introduction Bamlanivimab and etesevimab (BAM + ETE) are monoclonal antibodies (mAbs) effective in reducing COVID-19-related hospitalizations and all-cause…”
Get full text

SARS-CoV-2 Neutralizing Antibody LY-CoV555 in Outpatients with Covid-19 by Chen, Peter, Nirula, Ajay, Heller, Barry, Gottlieb, Robert L, Boscia, Joseph, Morris, Jason, Huhn, Gregory, Cardona, Jose, Mocherla, Bharat, Stosor, Valentina, Shawa, Imad, Adams, Andrew C, Van Naarden, Jacob, Custer, Kenneth L, Shen, Lei, Durante, Michael, Oakley, Gerard, Schade, Andrew E, Sabo, Janelle, Patel, Dipak R, Klekotka, Paul, Skovronsky, Daniel M

“…In a phase 2 trial, outpatients with Covid-19 who received a single infusion of a 2800-mg dose of the neutralizing antibody LY-CoV555 had a greater reduction…”
Get full text

Effect of Bamlanivimab as Monotherapy or in Combination With Etesevimab on Viral Load in Patients With Mild to Moderate COVID-19: A Randomized Clinical Trial by Gottlieb, Robert L, Nirula, Ajay, Chen, Peter, Boscia, Joseph, Heller, Barry, Morris, Jason, Huhn, Gregory, Cardona, Jose, Mocherla, Bharat, Stosor, Valentina, Shawa, Imad, Kumar, Princy, Adams, Andrew C, Van Naarden, Jacob, Custer, Kenneth L, Durante, Michael, Oakley, Gerard, Schade, Andrew E, Holzer, Timothy R, Ebert, Philip J, Higgs, Richard E, Kallewaard, Nicole L, Sabo, Janelle, Patel, Dipak R, Klekotka, Paul, Shen, Lei, Skovronsky, Daniel M

“…IMPORTANCE: Coronavirus disease 2019 (COVID-19) continues to spread rapidly worldwide. Neutralizing antibodies are a potential treatment for COVID-19…”
Get full text

Bamlanivimab plus Etesevimab in Mild or Moderate Covid-19 by Dougan, Michael, Nirula, Ajay, Azizad, Masoud, Mocherla, Bharat, Gottlieb, Robert L, Chen, Peter, Hebert, Corey, Perry, Russell, Boscia, Joseph, Heller, Barry, Morris, Jason, Crystal, Chad, Igbinadolor, Awawu, Huhn, Gregory, Cardona, Jose, Shawa, Imad, Kumar, Princy, Adams, Andrew C, Van Naarden, Jacob, Custer, Kenneth L, Durante, Michael, Oakley, Gerard, Schade, Andrew E, Holzer, Timothy R, Ebert, Philip J, Higgs, Richard E, Kallewaard, Nicole L, Sabo, Janelle, Patel, Dipak R, Dabora, Matan C, Klekotka, Paul, Shen, Lei, Skovronsky, Daniel M

“…In a phase 3 trial involving 1035 outpatients who were at increased risk for severe Covid-19, those who received two monoclonal antibodies targeting SARS-CoV-2…”
Get full text

Linking interferon regulatory factors to the pathogenesis of human lupus by Patel, Dipak R., MD, PhD

Get full text

A Randomized, Placebo-Controlled Clinical Trial of Bamlanivimab and Etesevimab Together in High-Risk Ambulatory Patients With COVID-19 and Validation of the Prognostic Value of Persistently High Viral Load by Dougan, Michael, Azizad, Masoud, Mocherla, Bharat, Gottlieb, Robert L, Chen, Peter, Hebert, Corey, Perry, Russell, Boscia, Joseph, Heller, Barry, Morris, Jason, Crystal, Chad, Igbinadolor, Awawu, Huhn, Gregory, Cardona, Jose, Shawa, Imad, Kumar, Princy, Blomkalns, Andra, Adams, Andrew C, Van Naarden, Jacob, Custer, Kenneth L, Knorr, Jack, Oakley, Gerard, Schade, Andrew E, Holzer, Timothy R, Ebert, Philip J, Higgs, Richard E, Sabo, Janelle, Patel, Dipak R, Dabora, Matan C, Williams, Mark, Klekotka, Paul, Shen, Lei, Skovronsky, Daniel M, Nirula, Ajay

“…Abstract Background Based on interim analyses and modeling data, lower doses of bamlanivimab and etesevimab together (700/1400 mg) were investigated to…”
Get full text

Epigenetics in 2013. DNA methylation and miRNA: key roles in systemic autoimmunity by Richardson, Bruce C, Patel, Dipak R

“…Several advances in 2013 have improved our understanding of how epigenetic mechanisms affect autoimmune disorders. Many new insights were made into the…”
Get full text

A Narrative Review of the Clinical Practicalities of Bamlanivimab and Etesevimab Antibody Therapies for SARS-CoV-2 by Nathan, Ramesh, Shawa, Imad, De La Torre, Inmaculada, Pustizzi, Jennifer M., Haustrup, Natalie, Patel, Dipak R., Huhn, Gregory

“…The severity of coronavirus disease 2019 (COVID-19) ranges from mild to death, with high morbidity and mortality rates reported amongst a vulnerable subset of…”
Get full text

Dissecting complex epigenetic alterations in human lupus by Patel, Dipak R, Richardson, Bruce C

“…Systemic lupus erythematosus is a chronic relapsing autoimmune disease that primarily afflicts women, and both a genetic predisposition and appropriate…”
Get full text

Epigenetic mechanisms in lupus by Patel, Dipak R, Richardson, Bruce C

“…PURPOSE OF REVIEWEpigenetic mechanisms regulate gene expression, and epigenetic gene dysregulation is implicated in the pathogenesis of a growing number of…”
Get full text

Aberrant Expression of Fas Ligand in Mice Deficient for the MHC Class II Transactivator by Gourley, Tania S, Patel, Dipak R, Nickerson, Kevin, Hong, Soon-Cheol, Chang, Cheong-Hee

“…The MHC class II transactivator (CIITA) is a critical regulator of MHC class II genes and other genes involved in the Ag presentation pathway. CIITA-deficient…”
Get full text

Bamlanivimab and Etesevimab Improve Symptoms and Associated Outcomes in Ambulatory Patients at Increased Risk for Severe Coronavirus Disease 2019: Results From the Placebo-Controlled Double-Blind Phase 3 BLAZE-1 Trial by Chen, Peter, Behre, Gerhard, Hebert, Corey, Kumar, Princy, Farmer Macpherson, Lisa, Graham-Clarke, Peita Louise, De La Torre, Inmaculada, Nichols, Russell M, Hufford, Matthew M, Patel, Dipak R, Naegeli, April N

“…Abstract Background In the phase 2/3 BLAZE-1 trial, bamlanivimab and etesevimab together reduced coronavirus disease 2019 (COVID-19)–related hospitalizations…”
Get full text

DNA methylation and miRNA—key roles in systemic autoimmunity by Richardson, Bruce C., Patel, Dipak R.

“…Several advances in 2013 have improved our understanding of how epigenetic mechanisms affect autoimmune disorders. Many new insights were made into the…”
Get full text

Thymic selection pathway regulates the effector function of CD4 T cells by Li, Wei, Sofi, M Hanief, Yeh, Norman, Sehra, Sarita, McCarthy, Brian P, Patel, Dipak R, Brutkiewicz, Randy R, Kaplan, Mark H, Chang, Cheong-Hee

“…Recently, a new developmental pathway for CD4 T cells that is mediated by major histocompatibility complex class II-positive thymocytes was identified (Choi,…”
Get full text

Altered Th1 Cell Differentiation Programming by CIITA Deficiency by Patel, Dipak R, Kaplan, Mark H, Chang, Cheong-Hee

“…CD4 T cell differentiation is a complex process affected by many transcription factors interacting in a tightly regulated manner. We have previously shown that…”
Get full text